Valuation: Immatics N.V.

Market Cap 929M 847M 783M 707M 1.33B 86.8B 1.38B 9.46B 3.74B 46.85B 3.48B 3.41B 148B P/E 2026 *
-2.83x
P/E 2027 * -2.9x
Enterprise Value 607M 554M 512M 462M 870M 56.73B 904M 6.18B 2.44B 30.62B 2.28B 2.23B 96.69B EV / Sales 2026 *
17.1x
EV / Sales 2027 * 21.4x
Free-Float
76.67%
Yield 2026 *
-
Yield 2027 * -
1 day-3.02%
1 week-8.82%
Current month-15.28%
1 month-9.36%
3 months-32.89%
6 months-42.56%
Current year-41.90%
1 week 5.95
Extreme 5.95
6.57
1 month 5.95
Extreme 5.95
7.95
Current year 5.95
Extreme 5.95
11.94
1 year 5.95
Extreme 5.95
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
14
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 31/12/2018
Director of Finance/CFO 57 30/09/2025
Chief Tech/Sci/R&D Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 51 30/06/2020
Chairman 70 30/09/2012
Director/Board Member 72 30/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26
Perceptive Advisors LLC
BuyCompany 863,060 0.6436%
18/03/26 Other

Chief Financial Officer

350,000 0.2611%
18/03/26 Other

Head of Human Resources

211,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-3.02%-8.82%-40.89%-29.72% 860M
-1.34%-3.09%+56.10%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.01% 58.86B
+0.54%+0.45%+25.96%+87.77% 55.22B
-2.34%-3.90%+10.90%+115.97% 47.21B
+0.09%-6.08%+18.67%+25.90% 42.45B
-2.58%+0.24%+18.54%+41.28% 36.44B
-1.76%-11.56%+126.44%+649.27% 35.19B
-0.17%-1.83%+82.46%+57.69% 32.66B
-1.69%-0.79%-40.58%+382.68% 26.73B
Average -1.17%-4.42%+26.66%+148.97% 40B
Weighted average by Cap. -0.85%-3.65%+34.06%+143.60%

Financials

2026 *2027 *
Net sales 35.22M 32.12M 29.7M 26.8M 50.48M 3.29B 52.47M 359M 142M 1.78B 132M 129M 5.61B 31.4M 28.64M 26.48M 23.89M 45M 2.93B 46.78M 320M 126M 1.58B 118M 115M 5B
Net income -303M -276M -255M -231M -434M -28.31B -451M -3.09B -1.22B -15.28B -1.14B -1.11B -48.26B -337M -307M -284M -256M -483M -31.49B -502M -3.43B -1.36B -17B -1.26B -1.24B -53.67B
Net Debt -322M -293M -271M -245M -461M -30.07B -479M -3.28B -1.3B -16.23B -1.21B -1.18B -51.24B -253M -231M -214M -193M -363M -23.66B -377M -2.58B -1.02B -12.77B -950M -930M -40.33B
Projected Income Statement - Annual - Immatics N.V.
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
721
Date Price Change Volume
18/11/26 US$6.100 -3.02% 1,571,164
17/11/26 US$6.290 +1.94% 3,164,202
16/11/26 US$6.170 -3.44% 762,157
13/11/26 US$6.390 -1.99% 586,386
12/11/26 US$6.520 -2.54% 809,266
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immatics N.V.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.100USD
Average target price
16.03USD
Spread / Average Target
+162.76%
  1. Stock Market
  2. Stocks
  3. IMTX Stock